Article

Explanting phakic IOLs requires caution, individualized approach

The growing popularity and long-term use of phakic IOLs inevitably will lead to more explantations, with cataract removal and with or without clear lens removal. An ophthalmologist outlines key steps to success.

Key Points

Nantes, France-Explantation of phakic IOLs will become more common as these lenses are implanted more frequently and used for longer periods. When explantation is required, it is important to choose the appropriate surgical technique for each patient, said Danuta Horodynska, MD, of Clinique Sourdille, Nantes, France.

She described cases involving 13 eyes of eight patients with different types of phakic IOLs, including iris-claw, angle-supported anterior chamber, and posterior chamber designs. The patients were treated with phakic IOL removal, lens removal, and posterior chamber IOL implantation (surgeries were performed by co-author Jean-Michel Bosc, MD). The lenses were explanted as a result of cataract in seven eyes, phakic IOL subluxation in one eye, and endothelial cell loss in five eyes.

The technique used to remove anterior chamber rigid phakic IOLs (of either angle-supported or iris-claw design) involved performing phacoemulsification before explantation, which allowed use of a small-incision technique. All steps in phaco were performed under the phakic implant. In the case of an iris-claw phakic IOL, the surgeon had to desenclavate one claw to allow enough space for instruments. The other claw was desenclavated after phaco, just before the incision was enlarged for the explantation. In eyes with high myopia, capsular tension rings were implanted.

Lens type important

The type of lens to be implanted after the explantation is an important consideration, Dr. Horodynska said. Some of the choices made by the surgical team included "in-the-bag" implantation of a multifocal IOL or a "piggyback" technique in which a monofocal IOL was placed in the bag and a multifocal presbyopic IOL was placed in the sulcus (in cases of multifocal phakic IOLs explantation).

The primary issues pertaining to phakic IOL explantation include protection of the endothelium during the operation, whether to explant the lens before or after phaco, and whether to remove only the phakic IOL in eyes without cataract or also to remove the clear lens, Dr. Horodynska said.

"In our opinion, if you operate on just one eye of the patient with bilateral phakic IOLs, you have to do clear lens removal to be able to handle postoperative anisometropia. The same is true with one-eye multifocal phakic IOL explantation, to ensure bilateral multifocality," she said.

The power needed in the new implant can be calculated with optical biometry (IOL Master, Carl Zeiss Meditec) or, with somewhat more difficulty, using ultrasound biometry, she said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.